XML 11 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 50,482,000 $ 81,553,000
Short-term investments 0 121,898,000
Accounts receivable, net 481,000 5,121,000
Inventories 3,155,000 17,173,000
Prepaid expenses and other current assets 31,542,000 40,038,000
Current assets held for sale 110,849,000 65,776,000
Total current assets 196,509,000 331,559,000
Restricted time deposits 0 1,658,000
Property and equipment, net 0 4,785,000
Operating lease right-of-use assets 0 64,939,000
Other assets 1,405,000 2,538,000
Long-term assets held for sale 16,611,000 18,050,000
Total assets 214,525,000 423,529,000
Current liabilities:    
Accounts payable 5,064,000 15,778,000
Accrued and other current liabilities 62,035,000 132,987,000
Deferred revenue 27,290,000 12,740,000
Operating lease liabilities, current 0 12,647,000
Current liabilities held for sale 38,917,000 43,516,000
Total current liabilities 133,306,000 217,668,000
Product development obligations 17,012,000 17,763,000
Deferred revenue, net of current 114,708,000 157,555,000
Operating lease liabilities, non-current 0 65,033,000
Senior secured term loan facilities, non-current 73,092,000 71,934,000
Liability related to sale of future revenues, non-current 58,864,000 51,413,000
Other long-term liabilities 822,000 2,858,000
Long-term liabilities held for sale 356,000 1,504,000
Total liabilities 398,160,000 585,728,000
Commitments and Contingencies (Note 12)  
Redeemable non-controlling interests 21,480,000 21,480,000
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2024 and 2023
Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2024 and 2023; 100,917 and 98,770 shares issued and outstanding at December 31, 2024 and 2023 1,009,000 988,000
Additional paid-in capital 1,668,620,000 1,643,641,000
Accumulated other comprehensive loss (5,732,000) (6,875,000)
Accumulated deficit (1,889,499,000) (1,841,920,000)
Total stockholders' deficit attributable to FibroGen (225,602,000) (204,166,000)
Nonredeemable non-controlling interests 20,487,000 20,487,000
Total deficit (205,115,000) (183,679,000)
Total liabilities, redeemable non-controlling interests and deficit $ 214,525,000 $ 423,529,000